uniQure N.V. (QURE) Stock Price & How to Invest

uniQure N.V. is a Netherlands-based, Nasdaq-listed clinical-stage biotech developing adeno-associated virus (AAV) gene therapies for serious central-nervous-system and other genetic diseases. Its lead program is AMT-130, a one-time gene therapy for Huntington's disease, delivered surgically into the brain, that met its primary endpoint at three years with roughly 75% slowing of disease progression versus external controls in a Phase I/II study. The rest of the pipeline is earlier stage: AMT-162 for SOD1 ALS, AMT-260 for refractory mesial temporal lobe epilepsy, and AMT-191 for Fabry disease. The company already validated its platform once by developing Hemgenix, the hemophilia B gene therapy now commercialized by CSL Behring, which produces royalty income.

The investment picture is that of a single-asset biotech. Product revenue is minimal (a few million dollars a quarter, mostly license and royalty income), and the company runs a large net loss funding R&D and commercial preparation. What matters is AMT-130: uniQure reached agreement with the FDA that its three-year data can support a Biologics License Application under the accelerated-approval pathway, with the submission planned for the third quarter of 2026 and a potential decision as early as mid-2027. Because Huntington's has no approved disease-modifying therapy and decades of prior failures, a first approval could be transformative, while a setback would remove most of the thesis. A cash balance of roughly $587 million funds operations into the second half of 2029, giving runway through the key regulatory events.

uniQure is a single-asset biotech, so any negative surprise on AMT-130, whether a Complete Response Letter, a request for a controlled confirmatory trial before approval, manufacturing questions, or safety concerns from an invasive brain-delivery procedure, could sharply reduce the company's value. The accelerated-approval pathway still requires alignment with the FDA on a confirmatory study, and there is precedent for the agency demanding more evidence in neurology. The rest of the pipeline is early and unproven, so it offers limited support if the lead program falters. As a pre-profit company, uniQure burns tens of millions per quarter and will likely need to raise capital again, which can dilute shareholders, and the stock is highly volatile and prone to large swings around clinical and regulatory news. Competition in Huntington's is also intensifying as rival mechanisms advance.

11 analysts publish price targets on QURE, averaging $69.63 against a $47.86 price as of September 2026, or +45.5%. The published targets run from $46.83 to $96.72, a wide spread, and the ratings split 11 buy, 1 hold, 0 sell. Over the last six months there have been 9 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full QURE forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on uniQure N.V.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. AMT-130 accelerated-approval path. The FDA has agreed that AMT-130's three-year Phase I/II data can serve as the primary basis for a BLA under the accelerated-approval pathway, and uniQure plans to submit in Q3 2026. The most optimistic published target, $96.72, assumes this works close to its best case.

The case against. uniQure is a single-asset biotech, so any negative surprise on AMT-130, whether a Complete Response Letter, a request for a controlled confirmatory trial before approval, manufacturing questions, or safety concerns from an invasive brain-delivery procedure, could sharply reduce the company's value. The most pessimistic target, $46.83, is roughly what QURE is worth if this bites instead.

Read the full bull and bear case on QURE, including what would have to change to break either one. Walnut is not an investment adviser.

No. uniQure N.V. (QURE) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see uniQure N.V.'s investor relations page or your broker.

• Revenue (Q1 2026): ~$3.6M (mostly license and royalty)
• Net loss (Q1 2026): ~$53.5M (~$0.85 per share)
• R&D expense (Q1 2026): ~$29M
• Cash and investments: ~$587M (into 2H 2029 runway)
• Share price: ~$39 (late July 2026)
• Market cap: ~$1.0-2.0B (moves sharply on news)

uniQure is pre-profit, so traditional valuation multiples like P/E do not apply and the stock is valued on the probability-weighted potential of its pipeline, chiefly AMT-130. Product revenue is minimal, with most of the small top line coming from Hemgenix royalties and license deals, while the company runs large losses funding development. The large cash balance relative to the market cap is a distinguishing feature, giving runway through the planned Q3 2026 BLA submission and beyond.

Other names that sit close to QURE: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get QURE exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so QURE sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where QURE fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

uniQure is a binary, catalyst-driven gene-therapy stock whose price hinges far more on the regulatory fate of its Huntington's therapy AMT-130 than on current revenue, which means the outcome distribution is unusually wide in both directions.

Whether QURE is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is QURE a buy or a sell?, and where the stock could go from here in the QURE stock forecast.

For income investors, whether QURE pays a dividend and how the payout looks is covered in does QURE pay a dividend? And to weigh QURE against a peer, read the full side-by-side comparisons: QURE vs IONS and QURE vs ASO.